244 related articles for article (PubMed ID: 21907198)
21. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.
Dutta S; Ware LA; Barbosa A; Ockenhouse CF; Lanar DE
Infect Immun; 2001 Sep; 69(9):5464-70. PubMed ID: 11500418
[TBL] [Abstract][Full Text] [Related]
22. Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.
Sachdeva S; Ahmad G; Malhotra P; Mukherjee P; Chauhan VS
Infect Immun; 2004 Oct; 72(10):5775-82. PubMed ID: 15385477
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
Vanloubbeeck Y; Pichyangkul S; Bayat B; Yongvanitchit K; Bennett JW; Sattabongkot J; Schaecher K; Ockenhouse CF; Cohen J; Yadava A;
Vaccine; 2013 Dec; 31(52):6216-24. PubMed ID: 24144477
[TBL] [Abstract][Full Text] [Related]
24. Study of the genetic discrimination between imported and autochthonous cases of malaria in South Korea.
Choi KM; Choi YK; Kang YA; Seo SY; Lee HW; Cho SH; Lee WJ; Rhie HG; Lee HS; Kim JY
J Travel Med; 2011; 18(1):63-6. PubMed ID: 21199147
[TBL] [Abstract][Full Text] [Related]
25. Plasmodium vivax merozoite surface protein 8 cloning, expression, and characterisation.
Perez-Leal O; Sierra AY; Barrero CA; Moncada C; Martinez P; Cortes J; Lopez Y; Torres E; Salazar LM; Patarroyo MA
Biochem Biophys Res Commun; 2004 Nov; 324(4):1393-9. PubMed ID: 15504368
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
27. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.
Bell BA; Wood JF; Bansal R; Ragab H; Cargo J; Washington MA; Wood CL; Ware LA; Ockenhouse CF; Yadava A
Vaccine; 2009 Feb; 27(9):1448-53. PubMed ID: 19138714
[TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of Plasmodium vivax clinical isolates in Pakistan and Iran using pvmsp-1, pvmsp-3alpha and pvcsp genes as molecular markers.
Zakeri S; Raeisi A; Afsharpad M; Kakar Q; Ghasemi F; Atta H; Zamani G; Memon MS; Salehi M; Djadid ND
Parasitol Int; 2010 Mar; 59(1):15-21. PubMed ID: 19545647
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
[TBL] [Abstract][Full Text] [Related]
30. Reactivity of sera from cases of Plasmodium vivax malaria towards three recombinant antigens based on the surface proteins of the parasite.
Suh IB; Choi HK; Lee SW; Woo SK; Kang HY; Won YD; Cho M; Lim CS
Ann Trop Med Parasitol; 2003 Jul; 97(5):481-7. PubMed ID: 12930610
[TBL] [Abstract][Full Text] [Related]
31. Cloning, expression, and characterisation of a Plasmodium vivax MSP7 family merozoite surface protein.
Mongui A; Perez-Leal O; Soto SC; Cortes J; Patarroyo MA
Biochem Biophys Res Commun; 2006 Dec; 351(3):639-44. PubMed ID: 17081497
[TBL] [Abstract][Full Text] [Related]
32. Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein.
Almeida AP; Dias MO; Vieira Cde A; Chávez-Olórtegui C; Gazzineli RT; Rodrigues MM; Fujiwara RT; Bruna-Romero O
Vaccine; 2014 Apr; 32(19):2181-7. PubMed ID: 24582631
[TBL] [Abstract][Full Text] [Related]
33. The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice.
Kim TS; Kim HH; Moon SU; Lee SS; Shin EH; Oh CM; Kang YJ; Kim DK; Sohn Y; Kim H; Lee HW
Exp Parasitol; 2011 Feb; 127(2):346-50. PubMed ID: 20801117
[TBL] [Abstract][Full Text] [Related]
34. Clinical expression and antigenic profiles of a Plasmodium vivax vaccine candidate: merozoite surface protein 7 (PvMSP-7).
Cheng CW; Jongwutiwes S; Putaporntip C; Jackson AP
Malar J; 2019 Jun; 18(1):197. PubMed ID: 31196098
[TBL] [Abstract][Full Text] [Related]
35. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.
Daly TM; Long CA
J Immunol; 1995 Jul; 155(1):236-43. PubMed ID: 7602100
[TBL] [Abstract][Full Text] [Related]
36. Vaccination with recombinant Plasmodium vivax MSP-10 formulated in different adjuvants induces strong immunogenicity but no protection.
Giraldo MA; Arevalo-Pinzon G; Rojas-Caraballo J; Mongui A; Rodriguez R; Patarroyo MA
Vaccine; 2009 Dec; 28(1):7-13. PubMed ID: 19782110
[TBL] [Abstract][Full Text] [Related]
37. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.
Yadava A; Nurmukhambetova S; Pichugin AV; Lumsden JM
J Infect Dis; 2012 May; 205(9):1456-63. PubMed ID: 22457289
[TBL] [Abstract][Full Text] [Related]
38. Probability of antibody formation against circumsporozoite protein of Plasmodium vivax among Korean malaria patients.
Nam HW; Song KJ; Ahn HJ; Yang Z; Chong CK; Cho PY; Ahn SK; Kim TS
Korean J Parasitol; 2014 Apr; 52(2):143-9. PubMed ID: 24850957
[TBL] [Abstract][Full Text] [Related]
39. Characterization of a novel merozoite surface protein of Plasmodium vivax, Pv41.
Cheng Y; Lu F; Tsuboi T; Han ET
Acta Trop; 2013 Jun; 126(3):222-8. PubMed ID: 23499861
[TBL] [Abstract][Full Text] [Related]
40. Antigenicity, immunogenicity, and protective efficacy of Plasmodium vivax MSP1 PV200l: a potential malaria vaccine subunit.
Valderrama-Aguirre A; Quintero G; Gómez A; Castellanos A; Pérez Y; Méndez F; Arévalo-Herrera M; Herrera S
Am J Trop Med Hyg; 2005 Nov; 73(5 Suppl):16-24. PubMed ID: 16291762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
